COVID-19 new case numbers on the rise again in the USA along with an increase by 27% of hospitalised COVID-9 patients - daily COVID-19 death numbers remain stagnant around 300 so still 2,000 to 3,000 succumbing to the virus each week in the USA
Statistics like these certainly support the need for Mesoblast's additional phase 3 Remestemcel-L COVID-19 ARDS trial ....
https://www.nytimes.com/
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-394
-
- There are more pages in this discussion • 512 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |